Luiz Octávio Pires
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Luiz Octávio Pires has a total of 54 co-authors. Here are the top co-authors by number of shared publications:
- Simone Odília Antunes Fernandes
Department of Clinical and Toxicological Analysis, Faculty of Pharmacy, Federal University of Minas Gerais, Belo Horizonte, Minas Gerais, Brazil
4 shared publications - Valbert Nascimento Cardoso
Departamento de Análises Clínicas e Toxicológicas, Faculdade de Farmácia, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil
4 shared publications - Amanda Dias Borges
Department of Clinical and Toxicological Analysis, Faculty of Pharmacy, Federal University of Minas Gerais, Belo Horizonte, Minas Gerais, Brazil
2 shared publications - Enio Ferreira
Departamento de Patologia Geral, Instituto de Ciências Biológicas, Universidade Federal de Minas Gerais, Belo Horizonte, MG, Brazil
2 shared publications - Flaviano Santos Martins
Departamento de Microbiologia, Instituto de Ciências Biológicas, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil
2 shared publications - Jacqueline Isaura Alvarez Leite
Universidade Federal de Minas Gerais
2 shared publications
Latest Publications
- Open Access
- 21 May 2026
- Published by Taylor & Francis in Gut Microbes Reports
- Vol. 3 (1)
Comparative preventive effects of probiotic and postbiotic preparations of Lacticaseibacillus rhamnosus L156.4 and GG in a 5-FU-induced mucositis model
Intestinal mucositis is a severe chemotherapy side effect, affecting up to 90% of patients. 1 It results from inflammation of the intestinal mucosa and is a common consequence of anticancer treatme...
- 21 May 2026
- Published by Taylor & Francis in Gut Microbes Reports
- Vol. 3 (1)
Open AccessComparative preventive effects of probiotic and postbiotic preparations of Lacticaseibacillus rhamnosus L156.4 and GG in a 5-FU-induced mucositis model
Intestinal mucositis is a severe chemotherapy side effect, affecting up to 90% of patients. 1 It results from inflammation of the intestinal mucosa and is a common consequence of anticancer treatme...
- Open Access
- 6 November 2025
- Published by Elsevier in Clinical Nutrition Open Science
- Vol. 64, 377-390
Vitamin C and L-arginine as potential synergistic adjuvants to recover intestinal mucositis induced by chemotherapy
- 6 November 2025
- Published by Elsevier in Clinical Nutrition Open Science
- Vol. 64, 377-390
Open AccessVitamin C and L-arginine as potential synergistic adjuvants to recover intestinal mucositis induced by chemotherapy
- 6 May 2024
- Published by Taylor & Francis in Journal of Chemotherapy
- Vol. 37 (2) , 175-192
Atorvastatin attenuates intestinal mucositis induced by 5-fluorouracil in mice by modulating the epithelial barrier and inflammatory response
Chemotherapy-induced intestinal mucositis is a major side effect of cancer treatment. Statins are 3-hydroxy-3-methyl glutaryl coenzyme reductase inhibitors used to treat hypercholesterolemia and atherosclerotic diseases. Recent studies have demonstrated that atorvastatin (ATV) has antioxidant, anti-inflammatory, and resulting from the regulation of different molecular pathways. In the present study, we investigated the effects of ATV on intestinal homeostasis in 5-fluorouracil (5-FU)-induced mucositis. Our results showed that ATV protected the intestinal mucosa from epithelial damage caused by 5-FU mainly due to inflammatory infiltrate and intestinal permeability reduction, downregulation of inflammatory markers, such as Tlr4, MyD88, NF-κB, Tnf-a, Il1β, and Il6 dose-dependent. ATV also improved epithelial barrier function by upregulating the mRNA transcript levels of mucin 2 (MUC2), and ZO-1 and occludin tight junction proteins. The results suggest that the ATV anti-inflammatory and protective effects on 5-FU-induced mice mucositis involve the inhibition of the TLR4/MYD88/NPRL3/NF-κB, iNos, and caspase 3.
- 6 May 2024
- Published by Taylor & Francis in Journal of Chemotherapy
- Vol. 37 (2) , 175-192
Atorvastatin attenuates intestinal mucositis induced by 5-fluorouracil in mice by modulating the epithelial barrier and inflammatory response
Chemotherapy-induced intestinal mucositis is a major side effect of cancer treatment. Statins are 3-hydroxy-3-methyl glutaryl coenzyme reductase inhibitors used to treat hypercholesterolemia and atherosclerotic diseases. Recent studies have demonstrated that atorvastatin (ATV) has antioxidant, anti-inflammatory, and resulting from the regulation of different molecular pathways. In the present study, we investigated the effects of ATV on intestinal homeostasis in 5-fluorouracil (5-FU)-induced mucositis. Our results showed that ATV protected the intestinal mucosa from epithelial damage caused by 5-FU mainly due to inflammatory infiltrate and intestinal permeability reduction, downregulation of inflammatory markers, such as Tlr4, MyD88, NF-κB, Tnf-a, Il1β, and Il6 dose-dependent. ATV also improved epithelial barrier function by upregulating the mRNA transcript levels of mucin 2 (MUC2), and ZO-1 and occludin tight junction proteins. The results suggest that the ATV anti-inflammatory and protective effects on 5-FU-induced mice mucositis involve the inhibition of the TLR4/MYD88/NPRL3/NF-κB, iNos, and caspase 3.